Literature DB >> 18953633

CpG-ODN enhances ingestion of apoptotic neutrophils by macrophages.

Jiong Wang1, Wei-Lin Huang, Rong-Yu Liu.   

Abstract

The clearance of apoptotic neutrophils by macrophages plays an important role in the process of inflammatory response. In the present study, we examined the ability of macrophages to ingest apoptotic neutrophils after activated by synthetic oligodeoxynucleotides containing CpG motifs (CpG-ODN) in vitro. The results showed that, while CpG-ODN at the experimental concentration had no cytotoxic effect on the viability of macrophages, the percentage of macrophages with ingested apoptotic neutrophils was increased from 23.6 to 42.30% by CpG-ODN stimulation. This effect was silenced when macrophages were treated with the mutation of CpG-ODN motifs. Both the total and cell surface protein of Toll-like receptor 9 (TLR9) expression in macrophages was up-regulated after CpG-ODN stimulation. While chloroquine (CHQ) had no effect on TLR9 expression in macrophages, it abolished the enhanced uptake of apoptotic neutrophils by macrophages. Although CpG-ODN had no significant effect on the IL-6 production, it was able to induce the increase of TNF-alpha protein expression and this effect was inhibited by CHQ pretreatment. Increased TNF-alpha production from macrophages induced by CpG-ODN stimulation was down-regulated after phagocytosis of apoptotic neutrophils. In conclusion, CpG-ODN could enhance the ingestion of apoptotic neutrophils by macrophages via TLR9 accompanied with an increasing in the level of TNF-alpha. After phagocytosis of apoptotic neutrophils, the increased TNF-alpha production from macrophages induced by CpG-ODN stimulation was down-regulated which the implications in the immune response remains for the further study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18953633     DOI: 10.1007/s10238-008-0017-x

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  40 in total

1.  In vivo ethanol exposure down-regulates TLR2-, TLR4-, and TLR9-mediated macrophage inflammatory response by limiting p38 and ERK1/2 activation.

Authors:  Joanna Goral; Elizabeth J Kovacs
Journal:  J Immunol       Date:  2005-01-01       Impact factor: 5.422

2.  Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents.

Authors:  S Ohkuma; B Poole
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

3.  The antimalarial artemisinin synergizes with antibiotics to protect against lethal live Escherichia coli challenge by decreasing proinflammatory cytokine release.

Authors:  Jun Wang; Hong Zhou; Jiang Zheng; Juan Cheng; Wei Liu; Guofu Ding; Liangxi Wang; Ping Luo; Yongling Lu; Hongwei Cao; Shuangjiang Yu; Bin Li; Lezhi Zhang
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  Macrophages from patients with SLE and rheumatoid arthritis have defective adhesion in vitro, while only SLE macrophages have impaired uptake of apoptotic cells.

Authors:  S W Tas; P Quartier; M Botto; L Fossati-Jimack
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

5.  The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets.

Authors:  Hiroaki Hemmi; Tsuneyasu Kaisho; Kiyoshi Takeda; Shizuo Akira
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

6.  Human alveolar epithelial cells engulf apoptotic eosinophils by means of integrin- and phosphatidylserine receptor-dependent mechanisms: a process upregulated by dexamethasone.

Authors:  D W Sexton; M G Blaylock; G M Walsh
Journal:  J Allergy Clin Immunol       Date:  2001-12       Impact factor: 10.793

7.  Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.

Authors:  Susana Mendez; Khaled Tabbara; Yasmine Belkaid; Sylvie Bertholet; Daniela Verthelyi; Dennis Klinman; Robert A Seder; David L Sacks
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

8.  Immune complexes bind preferentially to Fc gamma RIIA (CD32) on apoptotic neutrophils, leading to augmented phagocytosis by macrophages and release of proinflammatory cytokines.

Authors:  Simon P Hart; Karen M Alexander; Ian Dransfield
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

9.  Apoptotic cells inhibit LPS-induced cytokine and chemokine production and IFN responses in macrophages.

Authors:  Ioannis Tassiulas; Kyung-Hyun Park-Min; Yang Hu; Lisa Kellerman; Dror Mevorach; Lionel B Ivashkiv
Journal:  Hum Immunol       Date:  2007-01-08       Impact factor: 2.850

10.  CpG oligonucleotide activates Toll-like receptor 9 and causes lung inflammation in vivo.

Authors:  Pascal Knuefermann; Georg Baumgarten; Alexander Koch; Markus Schwederski; Markus Velten; Heidi Ehrentraut; Jan Mersmann; Rainer Meyer; Andreas Hoeft; Kai Zacharowski; Christian Grohé
Journal:  Respir Res       Date:  2007-10-09
View more
  3 in total

1.  TLR7 and TLR9 ligands regulate antigen presentation by macrophages.

Authors:  Teja Celhar; Selma Pereira-Lopes; Susannah I Thornhill; Hui Yin Lee; Manprit K Dhillon; Michael Poidinger; John E Connolly; Lina H K Lim; Subhra K Biswas; Anna-Marie Fairhurst
Journal:  Int Immunol       Date:  2015-11-13       Impact factor: 4.823

2.  Proinflammatory stimuli enhance phagocytosis of apoptotic cells by neutrophil granulocytes.

Authors:  Lars Hellberg; Sabrina Fuchs; Christoph Gericke; Arup Sarkar; Martina Behnen; Werner Solbach; Tamás Laskay
Journal:  ScientificWorldJournal       Date:  2011-11-15

3.  Prophylactic application of CpG oligonucleotides augments the early host response and confers protection in acute melioidosis.

Authors:  Barbara M Judy; Katherine Taylor; Arpaporn Deeraksa; R Katie Johnston; Janice J Endsley; Sudhamathi Vijayakumar; Judith F Aronson; D Mark Estes; Alfredo G Torres
Journal:  PLoS One       Date:  2012-03-20       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.